XOMA Royalty Corp (NASDAQ:XOMA), a $313 million market cap company, experienced a significant stock sale as reported in a recent SEC filing. Several major investors, including BVF Partners L.P., ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney ...

LOS ALTOS, Calif. - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a biotech company focusing on kidney disease treatments with a current market capitalization of $59 million, has shared insights from a ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Taysha Gene Therapies offers hope for Rett syndrome with innovative treatment, strong trial results, and promising regulatory ...

Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Shares of 89bio (NASDAQ:ETNB) were up 40% Monday afternoon, stoked by positive data for Akero Therapeutics' (NASDAQ:AKRO) drug efruxifermin in the treatment of compensated liver cirrhosis due to MASH.

A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...